ACTICOR BIOTECH has a total of 24 patent applications. Its first patent ever was published in 2016. It filed its patents most often in United States, Australia and Brazil. Its main competitors in its focus markets pharmaceuticals and biotechnology are FORTY SEVEN INC, BIONOMICS INC and TECHNOPHARM.
# | Country | Total Patents | |
---|---|---|---|
#1 | United States | 3 | |
#2 | Australia | 2 | |
#3 | Brazil | 2 | |
#4 | Canada | 2 | |
#5 | China | 2 | |
#6 | EPO (European Patent Office) | 2 | |
#7 | Israel | 2 | |
#8 | Republic of Korea | 2 | |
#9 | Mexico | 2 | |
#10 | WIPO (World Intellectual Property Organization) | 2 | |
#11 | Hong Kong | 1 | |
#12 | Singapore | 1 | |
#13 | Taiwan | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Biotechnology |
# | Technology | |
---|---|---|
#1 | Therapeutic chemical compounds | |
#2 | Medical preparations | |
#3 | Peptides |
# | Name | Total Patents |
---|---|---|
#1 | Billiald Philippe | 20 |
#2 | Jandrot-Perrus Martine | 15 |
#3 | Avenard Gilles | 10 |
#4 | Martine Jandrot-Perrus | 4 |
#5 | Jandrot Perrus Martine | 4 |
#6 | Philippe Billiald | 3 |
#7 | Gilles Avenard | 2 |
#8 | Philippe Billiard | 1 |
#9 | Jandrot-P Errus Martine | 1 |
Publication | Filing date | Title |
---|---|---|
KR20190121767A | Inhibition of platelet aggregation with anti-human GPVI antibodies | |
AU2016301969A1 | Novel anti-human GPVI antibodies and uses thereof |